Ohtuvayre (Ensifentrine)

Ohtuvayre (ensifentrine) is a dual phosphodiesterase 3 (PDE3) and phosphodiesterase 4 (PDE4) inhibitor designed for the maintenance treatment of chronic obstructive pulmonary disease (COPD) in adults. By targeting PDE3 and PDE4, Ohtuvayre helps improve lung function, reduce inflammation, and enhance breathing. This innovative therapy offers a new option for COPD management, providing significant relief to patients suffering from this chronic condition.

Recommended Dosage: The recommended dosage is 3 mg (one unit-dose ampule) administered twice daily, morning and evening. It is taken through oral inhalation using a standard jet nebulizer with a mouthpiece. Ensifentrine offers relief by helping open airways and improving lung function. For those with chronic obstructive pulmonary disease (COPD) or asthma, this treatment can enhance breathing.

• Ohtuvayre 3 mg/2.5 mL inhalation suspension is not intended for treating acute bronchospasm episodes. If an acute attack occurs, immediate treatment with a rescue inhaler should be sought. Consult your healthcare provider for proper management. Always carry emergency medications.
• Treatment with this medicine may cause paradoxical bronchospasm, which can be life-threatening. If symptoms worsen after using the medication, discontinue use immediately and seek medical attention. This rare reaction requires urgent medical intervention to prevent severe complications.
• Patients using Ensifentrine 3 mg/2.5 mL should be monitored for psychiatric events, including anxiety, depression, and suicidal thoughts. If any abnormal mental health changes occur, seek medical advice promptly. This precaution is critical, especially in patients with a history of mental illness.
• The use of Ensifentrine during pregnancy should only occur if needed, as its safety in pregnant women has not been fully established. Consult your healthcare provider to assess the potential risks and benefits before using this medication during pregnancy.
• This therapeutic drug may pass into breast milk. Mothers who are breastfeeding should consult their healthcare provider to evaluate the risks and benefits before using ensifentrine. Caution is advised, as the effects on the nursing infant are unknown.

What documents are required to import OHTUVAYRE to India?

How does the order be confirmed?

Indian Pharma Network can source the OHTUVAYRE (Cancer Treatment Medicines) from across the globe and can supply. Indian Pharma offers its customers worldwide access to the best available treatment.

Indian Pharma Network (IPN) can dispense any valid prescription in the shortest possible time. All prescriptions are dispensed and checked by registered pharmacists and dispatched to the Patient’s address only from New Delhi, India.

What is the Generic Name for the trade name drug Ohtuvayre®?

What are the most common side effects of Ohtuvayre®?